Generex has received a patent from the Canadian Intellectual Property Office for its aerosol drug delivery platform, its 162nd patent for the technology. Although the company announcement emphasizes its buccal delivery platform, the patent is titled Aerosol Formulations for Buccal and Pulmonary Application. Generex’s Oral-lyn buccal insulin spray is delivered via pMDI. Read the company’s press release.
Generex gets another Canadian patent for aerosol formulations
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
